Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company's principal SMDC product candidate, EC145, which is in Phase III clinical trial for the treatment of women with platinum-resistant ovarian cancer and in Phase IIb trial for second line pre-treated non-small cell lung cancer. Its preclinical development products include EC0531, a tubulysin conjugate to treat solid tumors; EC1069 for prostate cancer therapy; EC0746 and EC0565 foliate receptors for the reduction of inflammation; and EC0371, a foliate receptor for polycystic kidney disease. The company's products under development also comprise EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC20, a companion imaging diagnostic product, which is in Phase III clinical trial for the identification of folate receptor in cancer patients; and EC0652, a prostate cancer imaging agent.
Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.
Address
Suite A1-100 3000 Kent Avenue
WEST LAFAYETTE, IN 47906
United States
WEST LAFAYETTE, IN 47906
United States
Website
http://www.endocyte.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -18.32% | -49.86% |
| Operating margin | -18.34% | -46.26% |
| EBITD margin | - | -45.22% |
| Return on average assets | -6.74% | -10.00% |
| Return on average equity | -13.58% | -16.24% |
| Employees | 71 |
No comments:
Post a Comment